Gh Research Plc is a biotechnology company focused on developing innovative therapies for neurological disorders, particularly those related to psychedelics
The company is dedicated to harnessing the therapeutic potential of 5-MeO-DMT, a naturally occurring psychoactive compound, to create treatments aimed at addressing conditions such as depression and anxiety. By conducting rigorous research and clinical trials, Gh Research aims to advance the understanding and efficacy of psychedelic-assisted therapy, ultimately enhancing the quality of life for patients suffering from these challenging mental health issues. The company's mission emphasizes a commitment to scientific excellence and the responsible development of its products in the medical field.
GH Research's Phase 2b trial of GH001 for treatment-resistant depression met its primary endpoint, showing significant efficacy and a favorable safety profile.
While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are having growing pains.
The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a Portfolio of the 4 largest such companies.
Irish psychedelic biotech firm GH Research PLC (NASDAQGHRS) reported on Tuesday financial results for the second quarter ended June 30, 2024. Cash, cash equivalents, other financial assets and marketable securities were $204.5 million as of June 30, 2024, compared to cash, cash equivalents, other financial assets and marketable securities of $222.7 million as of December 31, 2023.The net loss was $10.4 million, or $0.20 loss per share, for the quarter that ended June 30, 2024, compared to the $7.7 million or $0.15 loss per share for the same quarter in 2023. The Dublin-based company also provided an update on its DMT-related drugs that are currently undergoing clinical trials.
Opportunities to invest in psychedelic stocks are emerging for those willing to get in early, and the 4 largest psychedelic compound-based portfolio drug discovery companies are up 5.9% in the past week.
This article highlights the 4 largest market cap clinical-stage psychedelic compound-based drug discovery companies with their stock performances MTD, in July, their areas of focus, and their latest news, analyses and commentary where available.
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average, in June and are now UP 13.8%, on average, YTD.
Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they were down 6% last week and -21.6% YTD.
Stocks for companies developing psychedelic treatments fell last Wednesday after advisers to the Food and Drug Administration voted against a mental-health therapy using the drug MDMA.
This article highlights the performances last week and MTD of the 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies along with their areas of focus in our Clinical-Stage BioTech Drug Stocks Portfolio.
